GV returned to help heart disease drug developer Tenaya boost its overall funding to approximately $248m.
US-based heart disease therapy developer Tenaya Therapeutics collected $106m yesterday in a series C round yesterday that included GV, a corporate venturing arm of technology conglomerate Alphabet. The round was led by investment firm RTW Investments and also featured investment and financial services group Fidelity, RA Capital Management, Column Group, Casdin Capital, funds and accounts…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.